BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
26.49
+0.28 (1.07%)
Dec 20, 2024, 4:00 PM EST - Market closed
BridgeBio Pharma Employees
As of December 31, 2023, BridgeBio Pharma had 556 total employees, including 550 full-time and 6 part-time employees. The number of employees increased by 160 or 40.40% compared to the previous year.
Employees
556
Change (1Y)
160
Growth (1Y)
40.40%
Revenue / Employee
$391,664
Profits / Employee
-$789,317
Market Cap
5.01B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
RadNet | 8,441 |
Stevanato Group | 5,634 |
Alkermes | 2,100 |
Tempus AI | 1,952 |
Corcept Therapeutics | 352 |
Crinetics Pharmaceuticals | 290 |
TG Therapeutics | 264 |
Krystal Biotech | 229 |
BBIO News
- 8 days ago - Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) - GlobeNewsWire
- 18 days ago - Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology - GlobeNewsWire
- 26 days ago - FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market - Benzinga
- 27 days ago - BridgeBio: Next Chapter Begins After Attruby Approval - Seeking Alpha
- 4 weeks ago - US FDA approves BridgeBio's drug for rare heart condition - Reuters
- 4 weeks ago - Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients - GlobeNewsWire
- 4 weeks ago - BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market - Benzinga
- 4 weeks ago - Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months - GlobeNewsWire